Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Regulus Therapeutics Inc. (RGLS)  
$2.02 0.10 (5.21%) as of 4:30 Fri 5/24


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 145,981,000
Market Cap: 294.88(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $1.13 - $2.88
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Regulus Therapeutics is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat diseases. Co.'s key product candidates are RG-012 and RGLS4326. RG-012 is an anti-miR targeting miR-21 for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease. Co. has multiple programs in various stages of preclinical development including RGLS5579 as a clinical candidate in its glioblastoma multiforme program, its preclinical programs targeting the Hepatitis B virus and Non-Alcoholic Steatohepatitis program.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 0 25,516 25,516 25,516
Total Sell Value $0 $30,379 $30,379 $30,379
Total People Sold 0 3 3 3
Total Sell Transactions 0 3 3 3
End Date 2024-02-25 2023-11-24 2023-05-26 2022-05-26

   
Records found: 341
  Page 13 of 14  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-05-29 4 AS $7.00 $6,209 D/D (887) 0     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-05-29 4 OE $0.38 $337 D/D 887 887     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-05-28 4 AS $7.00 $6,126 D/D (875) 0     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-05-28 4 OE $0.38 $333 D/D 875 875     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-05-27 4 AS $7.00 $12,203 D/D (1,743) 0     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-05-27 4 OE $0.38 $662 D/D 1,743 1,743     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-04-09 4 AS $8.11 $20,271 D/D (2,500) 80,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-04-09 4 OE $1.74 $4,350 D/D 2,500 82,500     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-03-06 4 AS $11.37 $28,429 D/D (2,500) 80,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-03-06 4 OE $1.74 $4,350 D/D 2,500 82,500     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-03-06 4 AS $11.35 $39,778 I/I (3,505) 80,216     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-03-06 4 OE $0.38 $1,332 I/I 3,505 83,721     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-02-06 4 OE $1.74 $78,300 D/D 45,000 80,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-02-05 4 AS $8.38 $146,706 D/D (17,500) 35,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-02-05 4 OE $1.74 $4,350 D/D 2,500 52,500     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-02-05 4 AS $8.40 $29,437 I/I (3,505) 80,216     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-02-05 4 OE $0.38 $1,332 I/I 3,505 83,721     -
   Sanofi-Aventis 10% Owner   –       –       •   2014-02-04 4 B $7.67 $9,999,993 I/I 1,303,780 5,053,779 1.5     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-01-21 4 AS $8.09 $35,764 D/D (4,421) 50,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-01-21 4 OE $2.66 $11,760 D/D 4,421 54,421     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-01-17 4 AS $8.15 $36,494 D/D (4,479) 50,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-01-17 4 OE $1.74 $9,706 D/D 4,479 54,479     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-01-16 4 AS $8.03 $8,837 D/D (1,100) 50,000     -
   Gibson Neil W Chief Scientific Officer   •       –      –    2014-01-16 4 OE $1.74 $1,914 D/D 1,100 51,100     -
   Xanthopoulos Kleanthis G President & CEO   •       •      –    2014-01-02 4 AS $7.25 $25,408 I/I (3,505) 80,216     -
  341 Records found
  Previous  10  11  12  13  14   
  Page 13 of 14
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us